No Result
View All Result
China Secrets Revealed
  • Economy
  • Editor’s Pick
  • Investing
  • News
  • Stock
  • Economy
  • Editor’s Pick
  • Investing
  • News
  • Stock
No Result
View All Result
China Secrets Revealed
No Result
View All Result
Home Economy

FDA officially authorizes Zyn nicotine pouches for sale following health review

by
January 17, 2025
in Economy
0
FDA officially authorizes Zyn nicotine pouches for sale following health review

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS
Previous Post

UnitedHealth CEO says U.S. health system ‘needs to function better’

Next Post

Treasury Department recoups $31 million in improper government payments to dead people

Next Post
Treasury Department recoups $31 million in improper government payments to dead people

Treasury Department recoups $31 million in improper government payments to dead people

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

0
TD Cowen downgrades Molson Coors, lowers price target to $58: Is it time to exit?

TD Cowen downgrades Molson Coors, lowers price target to $58: Is it time to exit?

0
Google’s antitrust ruling draws parallels to Microsoft’s 25-year-old case: Here’s how

Google’s antitrust ruling draws parallels to Microsoft’s 25-year-old case: Here’s how

0
In 2023, Colorado Lawmakers Pushed Back on Cops Practicing Pain Medicine Based on Flawed CDC Guideline

In 2023, Colorado Lawmakers Pushed Back on Cops Practicing Pain Medicine Based on Flawed CDC Guideline

0
Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

May 9, 2025
Trump’s tax hike proposal is ‘déjà vu’ of George H. W. Bush’s ‘read my lips’ moment, experts say

Trump’s tax hike proposal is ‘déjà vu’ of George H. W. Bush’s ‘read my lips’ moment, experts say

May 9, 2025
Friday Feature: MCP Academy

Friday Feature: MCP Academy

May 9, 2025
Trump pushes tax hikes for wealthy as ‘big, beautiful bill’ deadline looms

Trump pushes tax hikes for wealthy as ‘big, beautiful bill’ deadline looms

May 9, 2025

Recent News

Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

May 9, 2025
Trump’s tax hike proposal is ‘déjà vu’ of George H. W. Bush’s ‘read my lips’ moment, experts say

Trump’s tax hike proposal is ‘déjà vu’ of George H. W. Bush’s ‘read my lips’ moment, experts say

May 9, 2025
Friday Feature: MCP Academy

Friday Feature: MCP Academy

May 9, 2025
Trump pushes tax hikes for wealthy as ‘big, beautiful bill’ deadline looms

Trump pushes tax hikes for wealthy as ‘big, beautiful bill’ deadline looms

May 9, 2025

Disclaimer: ChinaSecretsRevealed.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 ChinaSecretsRevealed. All Rights Reserved.

No Result
View All Result
  • Economy
  • Editor’s Pick
  • Investing
  • News
  • Stock

Copyright © 2024 ChinaSecretsRevealed. All Rights Reserved.